Clinical Trials
42 trialsSARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration
Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1
National Institutes of Health Clinical Center (CC)
A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients
University Health Network, Toronto
Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery
Mayo Clinic
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Washington University School of Medicine
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
OHSU Knight Cancer Institute
Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma
Canadian Cancer Trials Group
PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma
Masonic Cancer Center, University of Minnesota
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Children's Oncology Group
Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma
Children's Oncology Group
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
OHSU Knight Cancer Institute
VORTEX
Sheffield Teaching Hospitals NHS Foundation Trust
Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy
National Institutes of Health Clinical Center (CC)
SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
Sarcoma Alliance for Research through Collaboration
Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration
Trial of Dasatinib in Advanced Sarcomas
Sarcoma Alliance for Research through Collaboration
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
National Cancer Institute (NCI)
HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors
Nationwide Children's Hospital
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
National Cancer Institute (NCI)
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
SWOG Cancer Research Network
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
National Cancer Institute (NCI)
Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery
University of Miami
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis
Alliance for Clinical Trials in Oncology
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
National Cancer Institute (NCI)
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients
SillaJen, Inc.
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Memorial Sloan Kettering Cancer Center
Sorafenib and Dacarbazine in Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
National Cancer Institute (NCI)
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
European Organisation for Research and Treatment of Cancer - EORTC
Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma
National Cancer Institute (NCI)
Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC